• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    O

    Ophthalmic Consultants of Boston

    院校
    431论文总数
    3万引用总数

    论文量&引用量时间轴

    机构学者

    论文(430)

    年份
    起
    –
    止
    排序
    1A Randomized Double-Masked Study Evaluating Safety and Efficacy of a Novel Topical Cooling Device for Chronic Ocular Surface Pain
    Anat Galor,Christopher Rapuano, Alice Epitropoulos, Jayne Weiss, Stephen Pflugfelder, Preeya Gupta, Deepinder Dhaliwal,Laura Periman, Bonnie An Henderson, Thanh T. Nguyen,Chameen Samarawickrama, Helen Wu,

    No therapy is currently FDA approved to treat ocular pain. This study evaluated the safety and efficacy of a novel topical ocular cooling device for chronic ocular surface pain (COSP). This was a prospective, randomized, double-masked, multicenter clinical feasibility study in adults aged 22–90 years with COSP. The intervention was a handheld device that applied cold temperatures to the conjunctival surface above the long ciliary nerves via two metallic contact surfaces at the 3 and 9 o’clock positions. Subjects were randomized 2:1 to a one-time, 4-min treatment with the active (frozen) or sham (refrigerated) device and followed for 8 weeks. Subjective pain was assessed via the visual analog scale (VAS), ocular pain assessment survey (OPAS), and chronic ocular pain questionnaire (COP-Q). Corneal sensitivity was evaluated with Cochet–Bonnet esthesiometry. Main outcomes were change from baseline in VAS, OPAS, and COP-Q scores. Post hoc analyses were conducted in eyes with peripheral-dominant pain based on proparacaine challenge. Adverse events (AEs) were recorded. Unilateral treatments were administered to 31 subjects (20 active, 11 sham). All three patient-reported outcomes (PROs) showed greater reductions in eye pain at week 8 in the active versus sham arm. In eyes with peripheral-dominant pain, COP-Q eye pain severity improved significantly versus sham at week 8 (nominal p = 0.042), and OPAS overall eye pain trended towards statistical significance (nominal p = 0.088). All three PROs exceeded thresholds for clinically meaningful improvement. Baseline corneal sensitivity was below normal in both groups and improved significantly only in the active group (nominal p = 0.041). No serious AEs occurred; the most common AE was transient conjunctival hyperemia. A novel ocular surface cooling device is well tolerated and appears to provide durable relief of COSP in peripheral-dominant pain types for at least 8 weeks. ClinicalTrials.gov identifier: NCT06479382.

    2026Ophthalmology and Therapy(2026)引用:21
    引用
    AI阅读
    加入学术空间
    2Avacincaptad Pegol for Geographic Atrophy: Pharmacokinetics and Immunogenicity from the GATHER2 Open-Label Extension
    Amit Desai,Jeffrey Heier, Gurundah R. Chichili, Anna Spence, Donna Cox, Zhiyue Huang, Olga Ceron,Laura L. Kovanda,Peter Kaiser
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    3Phase 1 Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
    Charles Clifton Wykof,Omer Trivizki,Jeffrey Heier,Paul S. Bernstein,Anat Loewenstein,Gregory S. Hageman,Burt T Richards, Eugene de Juan, Larry A. Wheeler, Laura Adamson, Jim Jin, Paulius Ojeras,
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    4Validation of At-Home OCT Imaging and AI Analytics in Neovascular Age-Related Macular Degeneration
    Anat Loewenstein,Miguel Busquets,Michael Elman,Sidney Schechet,Byron Ladd,Kapil Kapoor,Eric Schneider,Ella Leung,Alan Wagner,Krishna Mukkamala,Christopher Riemann, Seong Lee,
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    5Effect of Topical Bromfenac 0.09% on Pain Following Intravitreal Antivascular Endothelial Growth Factor Injections
    Kathryn Achuck, Rebecca Soares, Danielle Solish,Marko Popovic,Tina Felfeli,Rajeev Muni, Chirag Shah, Darrell Baskin,Jason Hsu, Sunir Garg

    Purpose: To evaluate the effect of topical bromfenac 0.09% on pain following intravitreal (IVT) injection of antivascular endothelial growth factor (anti-VEGF) medications in patients diagnosed as having choroidal neovascularization secondary to age-related macular degeneration or other etiologies, diabetic macular edema, diabetic retinopathy, or macular edema associated with retinal vein occlusion. Methods: A total of 78 adult patients scheduled to receive bilateral anti-VEGF IVT injections were randomized to receive topical bromfenac 0.09% in 1 eye and artificial tears in the fellow eye (control) immediately before the anti-VEGF treatment at 2 academic institutions from March 2021 to June 2022. Pain was evaluated using the Wong-Baker FACES Pain Rating Scale (score range, 0–10) and the Short-Form McGill Pain Questionnaire (score range, 0–5) at baseline (preinjection) and 5 minutes, 6 hours, and 24 hours following injection. Wilcoxon signed-rank sum test was used for statistical comparisons. Results: In total, 156 eyes were analyzed. Mean baseline pain scores were similar between the bromfenac 0.09% and control groups. Five minutes after injection, eyes randomized to receive bromfenac 0.09% had significantly less pain compared with control eyes receiving artificial tears, on both the Wong-Baker FACES scale (mean raw score, 2.29 vs 2.79; P = .0275) and the McGill Pain Questionnaire (mean raw score, 1.13 vs 2.36; P = .0135). No significant difference in pain scores was noted at 6 hours or 24 hours post–IVT injection. Conclusions: Bromfenac 0.09% solution administered to the study eye before IVT anti-VEGF injection reduced pain 5 minutes after injection in comparison with artificial tears. There was no difference in pain between the 2 groups at 6 hours or 24 hours post–IVT injection.

    2026Journal of VitreoRetinal Diseases(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 430 篇论文

    合作机构(100)

    Retina Vitreous Associates Medical Group合作论文 46
    再生元製藥合作论文 35
    Retina Consultants of Houston合作论文 32
    约翰斯·霍普金斯大学合作论文 28
    杜克大学合作论文 28
    Tennessee Retina合作论文 22
    拜耳合作论文 21
    波恩大学合作论文 19
    塔夫茨大学合作论文 18
    California Retina Consultants合作论文 18

    机构统计